Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics

Psychedelic treatments are emerging as promising interventions for many mental health conditions. These interventions are not offered in a standardized fashion across studies and between different healthcare centers. Beyond differences in substances and doses, there is also a great heterogeneity in the interventions provided by therapists. The current review offers a summary of important elements that should be reported when describing psychedelic-assisted therapies. Clinical trials involving psilocybin for depression are systematically reviewed to synthesize available descriptions of their interventions. This review demonstrates that the exact nature of these psychotherapeutic interventions tends to be poorly defined in most scientific papers on psychedelic treatments. This problem and its implications are examined. The field stands to gain from optimized psychotherapeutic methods; however, insufficient documentation in scientific papers currently hinders the dissemination and improvement of evidence-based protocols. This article offers ideas to encourage the progress of research on psychedelic-assisted therapies.

Authors

Institutions

Publication Details

Journal
Psychoactives
Published
2025-06-29
DOI
https://doi.org/10.3390/psychoactives4030021
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics

Mathieu Fradet
Psychoactives
Psychedelics and Drug Studies
article

Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics

Mathieu Fradet
article en

Abstract

Psychedelic treatments are emerging as promising interventions for many mental health conditions. These interventions are not offered in a standardized fashion across studies and between different healthcare centers. Beyond differences in substances and doses, there is also a great heterogeneity in the interventions provided by therapists. The current review offers a summary of important elements that should be reported when describing psychedelic-assisted therapies. Clinical trials involving psilocybin for depression are systematically reviewed to synthesize available descriptions of their interventions. This review demonstrates that the exact nature of these psychotherapeutic interventions tends to be poorly defined in most scientific papers on psychedelic treatments. This problem and its implications are examined. The field stands to gain from optimized psychotherapeutic methods; however, insufficient documentation in scientific papers currently hinders the dissemination and improvement of evidence-based protocols. This article offers ideas to encourage the progress of research on psychedelic-assisted therapies.

PsychoactivesVol. 4(3)
Université de Sherbrooke (CA), Palo Alto University (US), VA Palo Alto Health Care System (US), Stanford University (US)
Openalex Percentile: Top 78%
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics — Mathieu Fradet · Psychoactives (2025) | TGRS Research Map | TGRS